Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter clinical trials
- studies test it
- 9
- open now
- 0
- in phase 3
- 0
- first study started
- 2004
How each study uses Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
9 studies that test it; most in 2015 (2)
| Year | Studies |
|---|---|
| 2004 | 1 |
| 2011 | 1 |
| 2013 | 1 |
| 2014 | 1 |
| 2015 | 2 |
| 2017 | 2 |
| 2018 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 1 · Other 8
Mayo Clinic (6) · Sabine Mueller, MD, PhD (1) · Vyriad, Inc. (1) · University of Arkansas (1)
Often tested with
Tested in the same studies.
Carcinoembryonic Antigen-Expressing Measles Virus (1)
Studies
Open first, then newest update. How each study uses Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 9
- MV-NIS Infected Mesenchymal Stem Cells in Treating Recurrent Ovarian, Primary Peritoneal or Fallopian Tube CancerActive, not recruitingPhase 1/2Mayo ClinicNCT02068794Written as Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter
- MV-NIS or Investigator's Choice Chemotherapy in Treating Patients With Ovarian, Fallopian, or Peritoneal CancerTerminatedPhase 2Mayo ClinicNCT02364713Written as Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter
- Vaccine Therapy in Treating Patients with Malignant Peripheral Nerve Sheath Tumor That is Recurrent or Cannot Be Removed by SurgeryCompletedPhase 1Mayo ClinicNCT02700230Written as Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter
- Modified Measles Virus (MV-NIS) for Children and Young Adults With Recurrent Medulloblastoma or Recurrent ATRTCompletedPhase 1Sabine Mueller, MD, PhDNCT02962167Written as Modified Measles Virus
- Recombinant Measles Virus Vaccine Therapy and Oncolytic Virus Therapy in Treating Patients With Progressive, Recurrent, or Refractory Ovarian Epithelial Cancer or Primary Peritoneal CancerCompletedPhase 1Mayo ClinicNCT00408590Written as oncolytic measles virus encoding thyroidal sodium iodide symporter
- Trial of Intravesical Measles Virotherapy in Patients With Bladder Cancer Who Are Undergoing Radical CystectomyCompletedPhase 1Vyriad, Inc.NCT03171493Written as MV-NIS
- Viral Therapy In Treating Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Cancer or Metastatic Breast CancerCompletedPhase 1Mayo ClinicNCT01846091Written as Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter
- Intrapleural Measles Virus Therapy in Patients With Malignant Pleural MesotheliomaCompletedPhase 1Mayo ClinicNCT01503177Written as oncolytic measles virus encoding thyroidal sodium iodide symporter
- UARK 2014-21 A Phase II Trial of Oncolytic Virotherapy by Systemic Administration of Edmonston Strain of Measles VirusCompletedPhase 2University of ArkansasNCT02192775Written as MV-NIS
Given beside what is tested · 2 — Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter is usual care or a partner of the new treatment
- Dose Escalation Trial of Intra-Tumoral Injection of NIS Measles Virus in Combination With AtezolizumabTerminatedPhase 1Vyriad, Inc.NCT02919449Written as MV-NIS
- Vaccine Therapy With or Without Cyclophosphamide in Treating Patients With Recurrent or Refractory Multiple MyelomaCompletedPhase 1/2Mayo ClinicNCT00450814Written as Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter